Science

Mar 5, 2025, 11:23

Plasma ctDNA Kinetics Predicts Therapy Response in Advanced NSCLC – International Society of Liquid Biopsy

International Society of Liquid Biopsy shared an article by Luís F Leite da Silva, et al. on X:

“Plasma ctDNA Kinetics Predicts Therapy Response in Advanced NSCLC.

Key Findings from a Systematic Review & Meta-Analysis:

ctDNA clearance/decrease strongly correlates with improved PFS & OS in NSCLC patients.
HR for PFS: 0.32 (68% lower risk of progression with ctDNA clearance).
HR for OS: 0.31 (69% lower risk of death with ctDNA reduction).
Benefits seen across targeted therapy (TT) & immune checkpoint blockade (ICB).
Tumor-informed assays showed a stronger predictive value vs. tumor-agnostic assays.

Longitudinal ctDNA monitoring can revolutionize personalized NSCLC treatment decisions!

Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysis.

Authors: Luís F Leite da Silva, et al.

Plasma ctDNA Kinetics Predicts Therapy Response in Advanced NSCLC - International Society of Liquid Biopsy

cancer fight against cancer Global fight against cancer Immune checkpoint blockade International Society of Liquid Biopsy ISLB Luís F Leite da Silva non small cell lung cancer NSCLC OncoDaily Oncology plasma ctDNA targeted therapy

Beyond the Red Carpet: Oscar Winners and Nominees Who Fought Cancer

Oncologist Near Me – Lidia Schapira: A Leader in Cancer Care and Medical Education

CancerWorld welcomes their Co-Editors-in-Chief

Dr. Manette Le Grange joins OncoDaily Editorial Board

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma